Onesource Specialty Pharma Share Price Today | Stock Price & Onesource Specialty Pharma Share Screener
As of October 22, 2026, the live Onesource Specialty Pharma share price (NSE: ONESOURCE) is ₹1,377.80 on NSE and ₹1,382.60 on BSE, up 1.53% from the previous close, with shares trading between ₹1,326.30 and ₹1,385.30 in today's trading session, and a 52-week range of ₹1,114.00–₹1,877.80. Check ONESOURCE annual price range for the annual price range and momentum. Use the Onesource Specialty Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Onesource Specialty Pharma opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹453 and net income of ₹25, with EBITDA of ₹123, an operating margin of 27.0% and a profit margin of 5.5%.
Onesource Specialty Pharma Share Price Chart
Track the current stock price of Onesource Specialty Pharma with an interactive chart. Analyse ONESOURCE share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Onesource Specialty Pharma stock quote in one place.
The quote of ₹1,377.80 sits between the 52-week low of ₹1,114.00 and the 52-week high of ₹1,877.80, and the latest session moved 1.53% from the previous close.
Onesource Specialty Pharma Company Profile - Fundamental Screener
Screen Onesource Specialty Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ONESOURCE shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE013P01021.
Company Details
Classification
Identifiers and Leadership
Onesource Specialty Pharma Balance Sheet Screener
Screen ONESOURCE balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹8,210, up from ₹7,550 in 2025.
Latest statistics put total assets at ₹8,210 and shareholder funds at ₹5,831, with a leverage ratio of 0.17.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
Assets |
|||||||
| Total Assets | 8,210 | 7,550 | 1,309 | 2,009 | 2,442 | 1,258 | 972 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 6,017 | 6,118 | 863 | 1,361 | 1,231 | 633 | 354 |
Liabilities |
|||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 937 | 556 | 282 | 358 | 621 | 321 | 361 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
|||||||
| Total Equity | 5,831 | 5,881 | 396 | 786 | 1,013 | 776 | 417 |
| Share Capital | 12 | 11 | 4 | 4 | 3 | 2 | 1 |
| Reserves & Surplus | 5,819 | 5,869 | 392 | 781 | 1,009 | 775 | 414 |
Onesource Specialty Pharma Income Statement Screener - Profit & Revenue Analysis
Screen Onesource Specialty Pharma income statement and profit fundamentals. Analyze ONESOURCE quarterly results. Onesource Specialty Pharma reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Jun, revenue was ₹453 and net profit was ₹25, equal to earnings per unit of ₹2.18, at an operating margin of 27%.
In that period expenses were ₹330, interest cost ₹31 and tax ₹-5. The next period listed, 2026-Mar, shows revenue of ₹430 and net profit of ₹5.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||
| Revenue | 453 | 430 | 295 | 379 | 333 | 429 | 399 | 338 | 296 | 76 | 88 | 34 | 10 |
| Expenses | 330 | 336 | 280 | 269 | 242 | 244 | 351 | 263 | 233 | 76 | 173 | 105 | 80 |
Operating Costs and Margins | |||||||||||||
| EBITDA | 123 | 94 | 15 | 110 | 91 | 185 | 48 | 76 | 64 | 0 | -85 | -71 | -70 |
| Operating Profit % | 27.00% | 21.00% | 4.00% | 28.00% | 26.00% | 43.00% | 11.00% | 21.00% | 20.00% | -4.00% | -207.00% | -210.00% | -800.00% |
| Depreciation | 72 | 72 | 70 | 70 | 68 | 69 | 69 | 68 | 68 | 20 | 20 | 18 | 19 |
| Interest | 31 | 23 | 38 | 34 | 28 | 33 | 46 | 45 | 42 | 21 | 26 | 25 | 18 |
Profit and Earnings | |||||||||||||
| Profit Before Tax | 20 | 0 | -93 | 6 | -4 | 83 | -67 | -38 | -47 | -40 | -130 | -114 | -107 |
| Tax | -5 | -5 | -4 | -5 | -4 | -16 | 2 | 5 | -41 | 0 | 0 | 0 | 0 |
| Net Profit | 25 | 5 | -89 | 11 | 0 | 99 | -69 | -42 | -6 | -40 | -130 | -114 | -107 |
| EPS | 2.18 | 0.40 | -7.74 | 0.92 | -0.02 | 8.61 | -6.31 | -10.13 | -0.51 | -9.67 | -31.32 | -27.37 | 0.00 |
Onesource Specialty Pharma Cash Flow Screener - Liquidity Fundamentals
Screen ONESOURCE cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹9, and net cash flow was an outflow of ₹127.
Over the same period, investing activities used ₹495 and financing activities provided ₹359.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March |
|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||
| Operating Activities | 9 | -68 | -107 | -163 | -416 | -118 |
| Investing Activities | -495 | -201 | 511 | -68 | -692 | -207 |
Financing and Net Cash | ||||||
| Financing Activities | 359 | 412 | -391 | 118 | 1,162 | 381 |
| Net Cash Flow | -127 | 143 | 13 | -112 | 55 | 56 |
Onesource Specialty Pharma Shareholding Pattern Screener
See Onesource Specialty Pharma shareholding pattern with promoter, FII, and DII holdings. Check Onesource Specialty Pharma promoter holding and ownership changes for ONESOURCE on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Jun, promoters held 30.48%, foreign institutions 19.19%, domestic institutions 23.38% and the public 11.29%, spread across 77,899 shareholders.
The shareholder count was 77,899 in 2026-Jun, compared with 79,460 in 2026-Mar.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec |
|---|---|---|---|---|---|---|---|
Promoter Holding | |||||||
| Promoter Holding | 30.48% | 30.48% | 29.93% | 29.77% | 29.79% | 34.25% | 37.77% |
Institutional Investors | |||||||
| FII Holding | 19.19% | 17.50% | 19.24% | 19.39% | 18.69% | 18.54% | 17.44% |
| DII Holding | 23.38% | 20.61% | 18.81% | 18.49% | 18.10% | 18.04% | 12.56% |
Government, Public and Others | |||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 11.29% | 12.18% | 12.39% | 12.42% | 13.25% | 12.50% | 13.05% |
| Other Holding | 15.65% | 19.23% | 19.63% | 19.93% | 20.17% | 16.67% | 19.18% |
| Shareholder Count | 77,899 | 79,460 | 84,595 | 87,416 | 87,760 | 82,712 | 98,425 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Onesource Specialty Pharma. Onesource Specialty Pharma dividend yield can be compared with peers and other stocks in the market.
Onesource Specialty Pharma Stock Index Membership - Nifty & Sensex
See which indices include Onesource Specialty Pharma stock. Check ONESOURCE index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Onesource Specialty Pharma Market Events Screener - Corporate Actions
Get Onesource Specialty Pharma corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Onesource Specialty Pharma stock events that may affect ONESOURCE share price, along with derivatives, futures and options activity and sector gainers.
10 corporate actions are listed, the most recent entry being Annual General Meeting dated September 23, 2026, with a record date of September 23, 2026.
It is followed by Quarterly Result Announcement dated July 24, 2026 and Quarterly Result Announcement dated May 13, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-23 | 2026-09-23 | Annual General Meeting | NA | 3.55% |
| 2026-07-24 | 2026-07-24 | Quarterly Result Announcement | NA | 0.20% |
| 2026-05-13 | 2026-05-13 | Quarterly Result Announcement | NA | 5.21% |
| 2026-01-23 | 2026-01-23 | Quarterly Result Announcement | NA | -12.34% |
| 2025-11-11 | 2025-11-11 | Quarterly Result Announcement | NA | -1.91% |
| 2025-09-22 | 2025-09-22 | Annual General Meeting | NA | -1.03% |
| 2025-08-04 | 2025-08-04 | Quarterly Result Announcement | NA | -7.38% |
| 2025-05-05 | 2025-05-05 | Quarterly Result Announcement | NA | -0.05% |
| 2025-01-29 | 2025-01-29 | Quarterly Result Announcement | NA | - |
| 2024-02-14 | 2024-02-14 | Change Of Name | NA | - |
Onesource Specialty Pharma Competitors Screener - Peer Stocks Comparison
Screen ONESOURCE competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 418,204 | 34.85 | 61,674 | 12.69% | 11,565 | 34.47 |
| Divis Laboratories | 241,231 | 83.68 | 11,067 | 13.95% | 2,568 | 45.19 |
| Torrent Pharmaceuticals | 173,398 | 80.45 | 13,886 | 20.34% | 2,138 | 32.75 |
| Laurus Labs | 111,791 | 102.03 | 6,868 | 22.01% | 890 | 61.47 |
| Zydus Life Science | 111,112 | 24.42 | 27,658 | 17.64% | 5,026 | 42.73 |
| Cipla | 106,969 | 31.90 | 29,045 | 2.24% | 3,870 | 40.05 |
| Dr Reddys Laboratories | 103,709 | 32.30 | 35,059 | 3.90% | 4,158 | 59.92 |
| Aurobindo Pharma | 93,292 | 25.74 | 34,145 | 5.56% | 3,503 | 40.47 |
| Mankind Pharma | 93,067 | 45.45 | 14,636 | 14.85% | 1,938 | 36.17 |
| Lupin | 88,678 | 16.11 | 29,039 | 26.75% | 5,356 | 32.65 |
Onesource Specialty Pharma Company Announcements - News & Reports Screener
Screen ONESOURCE latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated September 25, 2026.
The next most recent announcements are dated September 25, 2026 and September 25, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-09-25 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-09-25 | Closure of Trading Window | - |
| 2026-09-25 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-09-23 | Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s | - |
| 2026-09-23 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-11 | General Update | - |
| 2026-09-03 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-09-01 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-31 | Notice Of The 19Th AGM Dated September 23 2026 | - |
| 2026-08-31 | Business Responsibility and Sustainability Reporting (BRSR) | - |
| 2026-08-31 | Reg. 34 (1) Annual Report. | - |
| 2026-08-31 | Reg. 34 (1) Annual Report. | - |
| 2026-08-31 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-08-29 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-18 | Announcement under Regulation 30 (LODR)-Credit Rating | - |
| 2026-07-31 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-07-27 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-07-26 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-25 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-07-24 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹1,377.80, within a 52-week range of ₹1,114.00 to ₹1,877.80. The P/E ratio is -332.24 and the P/B ratio is 2.77, with earnings per unit of ₹-6.44. Market capitalisation stands at ₹15,671.20 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 24, 2026. This page covers 7 balance sheet periods, 13 income statement periods, 6 cash flow years and 7 shareholding periods. Information is provided for research and is not investment advice.